









Markets
/
Stocks
/
nasdaq-livn
/

LivaNova PLC

LIVN

56.830USD

+2.890+5.36%

Close 11/04, 16:00（ET）Quotes delayed by 15 min

3.10BMarket Cap

LossP/E TTM



LivaNova PLC

56.830

+2.890+5.36%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of LivaNova PLC

Currency: USD Updated: 2025-11-04

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

LivaNova PLC's Score

Industry at a Glance

Industry Ranking

6 / 210

Overall Ranking

28 / 4616

Industry

Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 10 analysts

Buy

Current Rating

63.632

Target Price

+21.02%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

LivaNova PLC Highlights

StrengthsRisks

LivaNova PLC is a medical technology company. The Company designs, develops, manufactures, markets and sells products and therapies. Its segments include Cardiopulmonary, Neuromodulation and Advanced Circulatory Support (ACS). Cardiopulmonary segment is engaged in the design, development, manufacture, marketing and selling of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannula and other related accessories. It includes the Essenz Perfusion System, the Company’s next-generation HLM with an embedded patient monitor for tailored patient care strategies. Neuromodulation segment is engaged in the design, development, manufacture, marketing and selling of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). The ACS segment is engaged in the development, production, and sale of temporary life support products.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 22.67% year-on-year.

Fairly Valued

The company’s latest PE is -13.94, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 56.79M shares, decreasing 12.31% quarter-over-quarter.

Held by PRIMECAP Management

Star Investor PRIMECAP Management holds 4.64M shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-04

The company's current financial score is 9.25, which is higher than the Healthcare Equipment & Supplies industry's average of 7.46. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 352.52M, representing a year-over-year increase of 10.66%, while its net profit experienced a year-over-year increase of 66.30%.

Score

Industry at a Glance

Previous score

9.25

Change



Financials

8.56

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

9.92

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.78

Key Metrics

Free cash flow

No Data

LivaNova PLC's Company Valuation

Currency: USD Updated: 2025-11-04

The company’s current valuation score is 7.03, which is lower than the Healthcare Equipment & Supplies industry's average of 7.19. Its current P/E ratio is -13.94, which is -7305.05% below the recent high of 1004.49 and -1180.00% above the recent low of -178.45.

Score

Industry at a Glance

Previous score

7.03

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 6/210

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-04

The company’s current earnings forecast score is 8.20, which is higher than the Healthcare Equipment & Supplies industry's average of 7.74. The average price target for LivaNova PLC is 60.50, with a high of 80.00 and a low of 53.32.

Score

Industry at a Glance

Previous score

8.20

Change

Support & Resistance

No Data

Analyst Rating

Based on 10 analysts

Buy

Current Rating

63.632

Target Price

+21.02%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

110

Total

Median

Average

Company name

Ratings

Analysts

LivaNova PLC

LIVN

Medtronic PLC

MDT

Stryker Corp

SYK

Abbott Laboratories

ABT

Zimmer Biomet Holdings Inc

ZBH

Dexcom Inc

DXCM

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-04

The company’s current price momentum score is 8.76, which is higher than the Healthcare Equipment & Supplies industry's average of 6.77. Sideways: Currently, the stock price is trading between the resistance level at 56.03 and the support level at 51.12, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.14

Change

1.62

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

-0.129

Neutral

RSI(14)

52.729

Neutral

STOCH(KDJ)(9,3,3)

40.147

Buy

ATR(14)

1.229

High Vlolatility

CCI(14)

-62.050

Neutral

Williams %R

40.146

Buy

TRIX(12,20)

0.017

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

53.056

Buy

MA10

53.761

Buy

MA20

53.414

Buy

MA50

54.369

Buy

MA100

50.503

Buy

MA200

46.383

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-04

The company’s current institutional recognition score is 10.00, which is higher than the Healthcare Equipment & Supplies industry's average of 6.39. The latest institutional shareholding proportion is 104.00%, representing a quarter-over-quarter decrease of 0.11%. The largest institutional shareholder is PRIMECAP Management, holding a total of 4.64M shares, representing 8.50% of shares outstanding, with 2.91% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

6.37M

-2.31%

PRIMECAP Management Company

Star Investors

4.64M

+0.71%

The Vanguard Group, Inc.

Star Investors

2.44M

-8.09%

Millennium Management LLC

2.43M

+17.47%

State Street Investment Management (US)

2.08M

-0.83%

AQR Capital Management, LLC

2.05M

+30.45%

Dimensional Fund Advisors, L.P.

1.61M

+21.20%

Geode Capital Management, L.L.C.

1.43M

+1.31%

Wellington Management Company, LLP

1.28M

+170.32%

Artisan Partners Limited Partnership

1.25M

+112.86%

Risk Assessment

Currency: USD Updated: 2025-11-04

The company’s current risk assessment score is 7.52, which is higher than the Healthcare Equipment & Supplies industry's average of 4.57. The company's beta value is 1.04. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.